Wednesday, July 8, 2026

Patent intelligence · US

US 12409197

Synergistic bacterial compositions and methods of production and use thereof

granted A61KA61K2035/11A61K2035/115A61K35/74
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 36
Patent details — US 12409197
Jurisdiction
US
Status
granted
Grant date
Sep 9, 2025
Expiration
Sep 4, 2045
Claims
20
CPC classes
A61K, A61K2035/11, A61K2035/115, A61K35/74
View on Google Patents ↗

Quick answer

US 12409197 (Synergistic bacterial compositions and methods of production and use thereof) is held by Seres Therapeutics, Inc.. Status: granted. Granted Sep 9, 2025. Expires Sep 4, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K2035/11, A61K2035/115, A61K35/74, A61K35/742, A61K45/06

More from Seres Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12214002

    Compositions and methods for treating antibiotic resistance

    Seres Therapeutics, Inc. · Expires Jan 30, 2045

    granted
  2. US 12083151

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. · Expires Sep 5, 2044

    granted
  3. US 11918612

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. · Expires Feb 29, 2044

    granted
  4. US 11730775

    Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof

    Seres Therapeutics, Inc. · Expires Aug 17, 2043

    granted
  5. US 11701394

    Compositions and methods for treating cholestatic disease

    Seres Therapeutics, Inc. · Expires Jul 13, 2043

    granted
  6. US 11666612

    Network-based microbial compositions and methods

    Seres Therapeutics, Inc. · Expires Jun 1, 2043

    granted
  7. US 11464812

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. · Expires Oct 6, 2042

    granted

Frequently asked questions

What is US patent 12409197?

US 12409197 (Synergistic bacterial compositions and methods of production and use thereof) is held by Seres Therapeutics, Inc.. Status: granted. Granted Sep 9, 2025. Expires Sep 4, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12409197?

Seres Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.

When does US 12409197 expire?

Our index shows an expiration date of Sep 4, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.